NCT05887661Recruiting
Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy
The Application of Goal-directed Low Central Venous Pressure Based on Hypovolemic Phlebotomy in Laparoscopic Hepatectomy
Source: ClinicalTrials.gov · Last updated 12 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to learn about goal-directed LCVP based on hypovolemic phlebotomy (HP) in laparoscopic hepatectomy. The main questions it aims to answer are: 1. The safety and feasibility of HP 2. To evaluate whether HP can reduce perioperative blood transfusion ratio Participants undergoing liver resection with HP was performed by the anesthesiologist. Blood was withdrawn approximately 30 min prior to the initiation of liver parenchymal transection from central venous. The aim was to maintain the CVP between 0 to 5 cmH2O. HP volume was 5-10 mL/kg of patient body weight, generally. Participants in control group undergoing liver resection without HP.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 1 Mar 2023
- Start date
- 1 May 2022
- Primary completion date
- 1 Jan 2026
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT05887661
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 1 May 2022 to the primary completion date, 1 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, history of congestive heart failure)
- History of significant cerebrovascular disease
- Restrictive or obstructive pulmonary disease
- Uncontrolled hypertension
- Presence of active infection
Lab values
- Hemoglobin \<100 g/L
- Abnormal coagulation values (international normalized ratio \>1.5 not on warfarin and/or platelet count \<100 ×109/L)
- Evidence of hepatic metabolic disorder (bilirubin \>35 mmol/L)
Age
- Age \<18 years
Other
- Pregnancy
- Refusal of blood product transfusion
- Renal dysfunction (glomerular filtration rate \<60 mL/min),
- Preoperative autologous blood donation
- Patients were not allowed to receive erythropoietin at any time during the index hospitalization.
Who the study is looking for
- Clinical diagnosis of Hepatocellular Carcinoma
- Preference for laparoscopic hepatectomy and patient agreement
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Nanjing Medical University Coordinator of this site? Confirm its status | Nanjing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.